4:15 pm – 5:15 pm Friday, September 16

Hot Topics in Pediatric Oncology: Updates from the Children’s Oncology Group (C222)

Despite the pandemic, the Children’s Oncology Group (COG) has produced 237 publications since the beginning of 2020. The magnitude of this productivity makes it difficult for health care professionals to remain up to date with new knowledge. The purpose of this presentation is to highlight results from four recent, COG publications and assist nurses in translating evidence into their practice.  Read more...
8:30 am – 9:30 am Friday, September 16

General Session: State of Nursing: Pediatric Hematopoietic Stem Cell Transplantation: A Glimpse of the Past, Current State, a Glance of the Future (102)

Over the last 60 years, significant advances in in hematopoietic stem cell transplantation (HSCT) has provided improvements in effective treatment or cure and overall survival for many patients. There has been considerable HSCT progress and success in a variety of pediatric malignant and non-malignant diseases. This state of the science presentation will be providing the evolution and current and future highlights of Pediatric HSCT as it relates to disease conditions, stem cell sources, conditioning regimens, cellular immunotherapy, toxicity related treatments and supportive care. Read more...
3:00 pm – 4:00 pm Friday, September 16

General Session: Sickle Cell Disease: Pathophysiology, Pain, and Prevention of Problems (103)

Sickle Cell Disease (SCD) is the most common inherited hemoglobinopathy in the United States; the etiology is a DNA mutation that results in the different amino acids at position 6 of the beta-globin chain, where valine is produced instead of glutamine. The sickling of the red blood cell sets off a cascade of pathology. Vaso occlusion causing ischemia to almost every body system accounts for the majority of morbidity and is the etiology of acute pain episodes. Acute pain episodes account for the majority of health care utilization by this population.

2:15 pm – 3:15 pm Saturday, September 17

What the HEC is MEC? Understanding Antiemetic Therapy for Moderately and Highly Emetogenic Chemotherapy (230)

Optimal chemotherapy induced nausea and vomiting (CINV) control has been shown to improve patient’s quality of life and decrease distress. Without good control, both physical and psychological complications can occur, including anorexia, malnutrition, and nutritional deficiency. But what is optimal CINV control? Nausea without vomiting? No nausea? No vomiting? Only vomiting a few times? This definition can mean something different to every patient, provider, and nurse. Read more...
2:45 pm – 3:15 pm Saturday, September 17

Renewed Hope for the Future: Menin Inhibitors for Relapsed/Refractory Leukemia (233)

Prognosis for pediatric patients and adolescents with multiple relapsed/refractory leukemia remains grim. Many have received relapsed protocols, CAR-T therapies, stem cell transplants and yet, the disease returns. In the past, the next discussion in this patient population would lead towards palliation and quality of life, with little hope for cure. Recent advancement in therapy for children with refractory leukemia has introduced the use of menin inhibitor in patients with KMT2A/MLL and NPM1 mutations, providing a number of young patients with another chance of remission and a chance at a cure. Read more...
4:15 pm – 5:15 pm Friday, September 16

You Deserve to Preserve: A Proposal to Offer Fertility Preservation to All Eligible Pediatric Oncology Patients (221)

Fertility preservation, the opportunity to preserve one’s ability to have genetically-related children prior to damaging or destroying the reproductive system, is a young but rapidly expanding field. Historically, fertility preservation has only been available to postpubertal male and female cancer patients via oocyte, embryo, and sperm cryopreservation. Read more...
9:45 am – 10:45 am Friday, September 16

Photobiomodulation for Prevention and Treatment of Oral Mucositis: Part II (214)

Oral mucositis is a significant and common toxicity experienced by patients who receive high-dose chemotherapy as a preparatory regimen for a hematopoietic cell transplant (HCT). Photobiomodulation has been found to be feasible with significant efficacy in preventing the progression of oral mucositis in patients undergoing HCT. Read more...
9:45 am – 10:50 am Friday, September 16

Neurofibromatosis Therapeutics Program: Program Development, Tumor Treatment, and Side Effect Management (215)

The advanced practice provider is instrumental in designing, developing, and growing a program to treat tumors associated with Neurofibromatosis (NF) Type 1 and 2. Both NF1 and NF2 are autosomal dominant genetic disorders associated with the growth of both benign and malignant tumors of the peripheral and central nervous system. In the last two years selumetinib, a MEK inhibitor, gained FDA approval for treatment of plexiform neurofibromas in the children with NF. Read more...
4:15 pm – 5:15 pm Friday, September 16

It's All About the Messaging-Pediatric Palliative Care and Communication (218)

Each year, approximately 16,800 children are diagnosed with cancer. With this diagnosis comes both the hope for a cure and the fear of death. Both hope and fear require our attention and understanding. Children diagnosed with cancer need skilled intradisciplinary treatment teams that provide guidance and support in decisions related to therapy modalities aimed at treating the cancer. Aiming for cure is the hope of all children and families facing a cancer diagnosis. Goals of therapy become very important to designing the best treatment for the child.

Subscribe to this RSS feed